MentalHealthDaily

Early Parkinson’s Non-Motor Symptoms Differed by Sex After Levodopa

by GLOOM

MHD featured image for Parkinson's non-motor symptom sex differences.

A 2026 multicenter Italian cohort followed 216 early Parkinson’s disease patients for 24 months after levodopa initiation and found sex/gender differences in non-motor symptom burden.1 Women had higher anxiety, pain, mobility, and emotional-well-being burden, while men had higher hypersexuality. Research Highlights Longitudinal sample: The study followed 216 early levodopa-naive Parkinson patients, including 139 men and …

Entorhinal Dopamine Fails Early in Alzheimer’s Mice

by GLOOM

Editorial card showing the lateral entorhinal cortex with dopamine projections from the midbrain, illustrating an early-Alzheimer's mechanism finding rescued by L-DOPA in mice.

A 2026 Nature Neuroscience study from the Igarashi lab proposes a circuit-level answer for why the lateral entorhinal cortex (LEC) is the first cortical region to falter in Alzheimer’s: dopamine inputs from the VTA and substantia nigra to the LEC go functionally silent at the earliest disease stage in an APP knock-in mouse — before …

AI Levodopa Timing Improved UPDRS 4.4 Points in 5 Parkinson Patients

by GLOOM

MHD featured image for AI-guided levodopa dosing in Parkinson's disease.

A 2026 open-label feasibility trial involving 5 Parkinson’s disease patients found that app-randomized levodopa timing was associated with a mean 4.4-point improvement on the Unified Parkinson’s Disease Rating Scale, but the signal missed conventional statistical significance at p = 0.063.1 The narrow conclusion is feasibility: this was a dosing experiment that justified a blinded controlled …

Alpha-Synuclein SAA Predicts Parkinson’s Levodopa Response Durability

by GLOOM

Photoreal illustration of CSF biomarker testing alongside dopaminergic neuron pathways, representing PD biomarker stratification.

A 2026 PPMI analysis found that Parkinson’s patients with positive CSF α-synuclein seed amplification assay results kept gaining levodopa benefit over follow-up, while SAA-negative patients showed faster ON-medication motor progression than SAA-positive patients: 0.87 vs. 3.47 MDS-UPDRS Part III points/year in 183 matched SAA-positive and 40 SAA-negative patients.1 Research Highlights ON-state progression split sharply: SAA-positive …

Sinemet (Carbidopa-Levodopa) Side Effects & Adverse Reactions (List)

by GLOOM

Sinemet is a pharmaceutical drug engineered by Merck that combines Carbidopa (a peripheral enzymatic inhibitor of DOPA decarboxylase) and Levodopa (an agent that crosses the blood-brain barrier to increase central concentrations of dopamine); hence it is frequently referred to as “Carbidopa-Levodopa.” The drug was initially approved by the U.S. FDA in 1988 for the treatment …